CA ATLANTIQUE VENDEE-CCI (CRAV.PA) Stock Fundamental Analysis

EPA:CRAV • FR0000185506

135.7 EUR
+0.32 (+0.24%)
Last: Feb 24, 2026, 01:24 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CRAV. CRAV was compared to 108 industry peers in the Banks industry. Both the profitability and financial health of CRAV have multiple concerns. CRAV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CRAV was profitable.
  • CRAV had a negative operating cash flow in the past year.
  • CRAV had positive earnings in each of the past 5 years.
  • In multiple years CRAV reported negative operating cash flow during the last 5 years.
CRAV.PA Yearly Net Income VS EBIT VS OCF VS FCFCRAV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.24%, CRAV is doing worse than 90.74% of the companies in the same industry.
  • CRAV has a worse Return On Equity (1.94%) than 91.67% of its industry peers.
Industry RankSector Rank
ROA 0.24%
ROE 1.94%
ROIC N/A
ROA(3y)0.32%
ROA(5y)0.31%
ROE(3y)2.73%
ROE(5y)2.61%
ROIC(3y)N/A
ROIC(5y)N/A
CRAV.PA Yearly ROA, ROE, ROICCRAV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 1 2 3 4

1.3 Margins

  • CRAV has a worse Profit Margin (14.89%) than 84.26% of its industry peers.
  • CRAV's Profit Margin has declined in the last couple of years.
  • CRAV does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 14.89%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-9.77%
PM growth 5Y-7.27%
GM growth 3YN/A
GM growth 5YN/A
CRAV.PA Yearly Profit, Operating, Gross MarginsCRAV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • CRAV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CRAV has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CRAV has about the same amount of shares outstanding.
  • CRAV has a better debt/assets ratio than last year.
CRAV.PA Yearly Shares OutstandingCRAV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
CRAV.PA Yearly Total Debt VS Total AssetsCRAV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • A Debt/Equity ratio of 0.07 indicates that CRAV is not too dependend on debt financing.
  • CRAV's Debt to Equity ratio of 0.07 is amongst the best of the industry. CRAV outperforms 87.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC5.73%
CRAV.PA Yearly LT Debt VS Equity VS FCFCRAV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
CRAV.PA Yearly Current Assets VS Current LiabilitesCRAV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for CRAV have decreased by -0.18% in the last year.
  • CRAV shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -5.30% yearly.
  • CRAV shows a decrease in Revenue. In the last year, the revenue decreased by -0.96%.
  • Measured over the past years, CRAV shows a small growth in Revenue. The Revenue has been growing by 2.10% on average per year.
EPS 1Y (TTM)-0.18%
EPS 3Y-8.94%
EPS 5Y-5.3%
EPS Q2Q%-7.51%
Revenue 1Y (TTM)-0.96%
Revenue growth 3Y0.89%
Revenue growth 5Y2.1%
Sales Q2Q%-7.59%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRAV.PA Yearly Revenue VS EstimatesCRAV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 12.43, the valuation of CRAV can be described as correct.
  • Compared to the rest of the industry, the Price/Earnings ratio of CRAV indicates a slightly more expensive valuation: CRAV is more expensive than 64.81% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of CRAV to the average of the S&P500 Index (26.98), we can say CRAV is valued rather cheaply.
Industry RankSector Rank
PE 12.43
Fwd PE N/A
CRAV.PA Price Earnings VS Forward Price EarningsCRAV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRAV.PA Per share dataCRAV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1K 2K 3K

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. Dividend

5.1 Amount

  • CRAV has a Yearly Dividend Yield of 2.56%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 4.37, CRAV's dividend is way lower than its industry peers. On top of this 80.56% of the companies listed in the same industry pay a better dividend than CRAV!
  • Compared to an average S&P500 Dividend Yield of 1.81, CRAV pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 2.56%

5.2 History

  • The dividend of CRAV has a limited annual growth rate of 0.59%.
Dividend Growth(5Y)0.59%
Div Incr Years0
Div Non Decr Years0
CRAV.PA Yearly Dividends per shareCRAV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

DP0%
EPS Next 2YN/A
EPS Next 3YN/A
CRAV.PA Yearly Income VS Free CF VS DividendCRAV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

More info and screens

Find the best dividend stocksShow peers with best dividend

CA ATLANTIQUE VENDEE-CCI

EPA:CRAV (2/24/2026, 1:24:39 PM)

135.7

+0.32 (+0.24%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupBanks
GICS IndustryBanks
Earnings (Last)02-02
Earnings (Next)04-28
Inst Owners2.72%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap162.84M
Revenue(TTM)541.14M
Net Income(TTM)80.56M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.56%
Yearly DividendN/A
Dividend Growth(5Y)0.59%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 12.43
Fwd PE N/A
P/S 0.3
P/FCF N/A
P/OCF N/A
P/B 0.04
P/tB 0.04
EV/EBITDA N/A
EPS(TTM)10.92
EY8.05%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-350.73
FCFYN/A
OCF(TTM)-318.29
OCFYN/A
SpS450.95
BVpS3455.02
TBVpS3450.32
PEG (NY)N/A
PEG (5Y)N/A
Graham Number921.36
Profitability
Industry RankSector Rank
ROA 0.24%
ROE 1.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 14.89%
GM N/A
FCFM N/A
ROA(3y)0.32%
ROA(5y)0.31%
ROE(3y)2.73%
ROE(5y)2.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-9.77%
PM growth 5Y-7.27%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 175.95%
Cap/Sales 7.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score5
WACC5.73%
ROIC/WACCN/A
Cap/Depr(3y)179.19%
Cap/Depr(5y)167.09%
Cap/Sales(3y)6.69%
Cap/Sales(5y)6.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.18%
EPS 3Y-8.94%
EPS 5Y-5.3%
EPS Q2Q%-7.51%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.96%
Revenue growth 3Y0.89%
Revenue growth 5Y2.1%
Sales Q2Q%-7.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.49%
FCF growth 3Y-41.96%
FCF growth 5Y-14.64%
OCF growth 1Y67.7%
OCF growth 3Y-39.13%
OCF growth 5Y-12.88%

CA ATLANTIQUE VENDEE-CCI / CRAV.PA FAQ

What is the fundamental rating for CRAV stock?

ChartMill assigns a fundamental rating of 1 / 10 to CRAV.PA.


What is the valuation status for CRAV stock?

ChartMill assigns a valuation rating of 1 / 10 to CA ATLANTIQUE VENDEE-CCI (CRAV.PA). This can be considered as Overvalued.


What is the profitability of CRAV stock?

CA ATLANTIQUE VENDEE-CCI (CRAV.PA) has a profitability rating of 1 / 10.


What are the PE and PB ratios of CA ATLANTIQUE VENDEE-CCI (CRAV.PA) stock?

The Price/Earnings (PE) ratio for CA ATLANTIQUE VENDEE-CCI (CRAV.PA) is 12.43 and the Price/Book (PB) ratio is 0.04.


What is the financial health of CA ATLANTIQUE VENDEE-CCI (CRAV.PA) stock?

The financial health rating of CA ATLANTIQUE VENDEE-CCI (CRAV.PA) is 2 / 10.